- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.03. | Artelo Biosciences Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 25.03. | Recap: Artelo Biosciences Q4 Earnings | 1 | Benzinga.com | ||
| 25.03. | Artelo Biosciences GAAP EPS of -$3.14 misses by $0.58 | 1 | Seeking Alpha | ||
| 25.03. | Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update | 81 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop... ► Artikel lesen | |
| 25.03. | ARTELO BIOSCIENCES, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.03. | Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge | 2 | GlobeNewswire (USA) | ||
| 04.03. | ARTELO BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.02. | Artelo Biosciences, Inc.: Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th | 516 | ACCESSWIRE | SOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments... ► Artikel lesen | |
| 23.01. | Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy | 3 | GlobeNewswire (USA) | ||
| 08.01. | Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12 | 166 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments... ► Artikel lesen | |
| 13.11.23 | Artelo Biosciences GAAP EPS of -$0.83 misses by $0.18 | 1 | Seeking Alpha | ||
| 13.11.23 | Artelo Biosciences Inc reports results for the quarter ended in September - Earnings Summary | 1 | Reuters | ||
| 13.11.23 | Recap: Artelo Biosciences Q3 Earnings | 1 | Benzinga.com | ||
| 13.11.23 | ARTELO BIOSCIENCES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.23 | Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update | - | GlobeNewswire (USA) | ||
| 09.11.23 | Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers | 209 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments... ► Artikel lesen | |
| 02.11.23 | Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023 | 1 | GlobeNewswire (USA) | ||
| 07.09.23 | Pre-market Movers: Wheeler Real Estate Investment Trust, Sportsman's Warehouse, Artelo Biosciences, Verint Systems, Hitek Global | 825 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Wheeler Real Estate Investment Trust, Inc. (WHLR)... ► Artikel lesen | |
| 26.06.23 | Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium | 298 | GlobeNewswire (Europe) | ART12.11, a novel and patented cocrystal of CBD reverses the impact of chronic stress on outcomes of anxiety, depression, sociability and cognition ART12.11 aims to address unmet needs within the... ► Artikel lesen | |
| 11.05.23 | Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update | 1.333 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,20 | +0,74 % | BioNTech Aktie: Rückgang Trotz Forschungshoffnung | Die Aktie des Mainzer Biotechnologieunternehmens BioNTech setzt ihren negativen Trend fort, mit einem aktuellen Preis von 80,95 Euro und einem Rückgang von 0,31% im Vergleich zur Vorwoche. Trotz der... ► Artikel lesen | |
| CUREVAC | 2,254 | -2,26 % | CureVac Aktie: Hoffnung trotz Abwärtstrends? | CureVac-Aktien haben in der letzten Woche einen leichten Rückgang von 0,65 % hinnehmen müssen und notieren aktuell bei 2,75 €. Trotz der marginalen Erholung am Freitag um etwa 2 % bleibt das Papier... ► Artikel lesen | |
| QIAGEN | 37,470 | +1,19 % | Kursverluste für das Wertpapier von Qiagen NV (37,815 €) | An der Börse liegt der Anteilsschein von Qiagen NV gegenwärtig im Minus. Das Papier notiert derzeit bei 37,82 Euro. Ein Verlust von 0,79 Prozent steht gegenwärtig für das Wertpapier von Qiagen NV zu... ► Artikel lesen | |
| AMGEN | 251,05 | +1,70 % | Amgen Aktie: Tezspire als COPD-Potenzial | Amgen, der weltweit größte Biotech-Arzneimittelhersteller, hat in der jüngsten Marktschließung einen leichten Rückgang auf $264.07 verzeichnet, obwohl dies hinter dem allgemeinen Verlust des S&P 500... ► Artikel lesen | |
| NOVAVAX | 3,667 | +0,19 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| BIOGEN | 180,20 | +0,70 % | What's in Store for Biogen (BIIB) This Earnings Season? | ||
| PALATIN TECHNOLOGIES | 1,738 | -1,92 % | Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying | ||
| INOVIO PHARMACEUTICALS | 9,080 | -5,42 % | Pre-market Movers: Macatawa Bank, Ryvyl, WiSA Technologies, Inovio Pharmaceuticals, Mobilicom | STOCKHOLM (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.55 A.M. ET).In the Green Macatawa Bank Corporation (MCBC) is up over 38%... ► Artikel lesen | |
| MAINZ BIOMED | 0,850 | -1,51 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
| BIONXT SOLUTIONS | 0,272 | +1,49 % | BioNxt berichtet über die nächsten Schritte zur Markteinführung seines Produkts Cladrabine ODF für die Behandlung der Multiplen Sklerose | VANCOUVER, BRITISH COLUMBIA / ACCESSWIRE / 18. März 2024 / BioNxt Solutions Inc. ("BioNxt" oder das
"Unternehmen") (CSE: BNXT) (OTCQB: BNXTF) (FWB: BXT) freut sich bekannt zu geben, dass das... ► Artikel lesen | |
| AETERNA ZENTARIS | 1,820 | -1,62 % | Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris | TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 19,845 | -0,97 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 58,22 | -4,24 % | Viking Therapeutics (VKTX) to Report Q1 Earnings: What's in the Cards? | ||
| BIOCRYST PHARMACEUTICALS | 4,150 | -1,96 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency | RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval... ► Artikel lesen | |
| VAXART | 0,730 | -7,59 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the"Company"or"Vaxart") today announced that the Compensation Committee of the Board of Directors approved... ► Artikel lesen |
ARTELO BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,56 % bei einem Aktienkurs von 1,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
